Chinese innovator Shenogen raises new funds for ER-a36 platform
This article was originally published in Scrip
Executive Summary
With the $30 million it has just raised in a Series C financing, the Chinese drug development venture Shenogen Pharma Group is aiming to take its lead pipeline project through a Phase II proof-of-concept trial for advanced hepatocellular carcinoma (HCC).